Vor Biopharma Inc
$ 23.70
6.42%
06 Aug - close price
- Market Cap 1,206,719,000 USD
- Current Price $ 23.70
- High / Low $ 23.79 / 21.90
- Stock P/E N/A
- Book Value -2.78
- EPS -70.34
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -1.25 %
- 52 Week High 50.20
- 52 Week Low 6.50
About
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$37.88
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-30 | 2025-11-13 | 2025-08-12 | 2025-05-14 | 2025-03-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-07 | 2023-08-10 |
| Reported EPS | -0.73 | 307.53 | -121.63 | -251.2 | -5.2 | -0.44 | -8 | -8.2 | -9 | -0.39 | -9.8 | -9 |
| Estimated EPS | -0.78 | -1.191 | -4.1 | -11.8 | -4.16 | -0.3067 | -0.4 | -8.29 | -7.63 | -0.5 | -9.17 | -8.46 |
| Surprise | 0.05 | 308.721 | -117.53 | -239.4 | -1.04 | -0.1333 | -7.6 | 0.09 | -1.37 | 0.11 | -0.63 | -0.54 |
| Surprise Percentage | 6.4103% | 25921.1587% | -2866.5854% | -2028.8136% | -25% | -43.4627% | -1900% | 1.0856% | -17.9554% | 22% | -6.8702% | -6.383% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.69 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VOR
2026-08-06 14:40:56
FMR LLC has disclosed a 9.1% beneficial ownership stake in Vor Biopharma Inc. (VOR), amounting to 4,932,149 shares of common stock as of June 30, 2026. The filing indicates FMR LLC holds sole dispositive power and nearly all sole voting power over these shares. Abigail P. Johnson also holds sole dispositive power over the same number of shares, though no voting power.
2026-08-05 16:59:52
Vor Biopharma (NASDAQ: VOR) is set to report its second-quarter results, with investors keenly watching for improvements after a significant first-quarter loss. Analysts project a loss of 73 cents per share, a substantial improvement from the previous quarter's $5.11 loss, and maintain an optimistic long-term outlook with a consensus "Strong Buy" rating and a target price of $37.88. Key areas of focus for investors include the company's cash burn rate, progress in its Phase 3 clinical trials for telitacicept, and potential revenue generation from recent regulatory approvals in China.
2026-08-03 15:30:00
Vor Bio announced that its Compensation Committee granted stock options and restricted stock units (RSUs) to five newly hired employees as material inducements for employment. These grants, totaling 32,550 stock options and 6,900 RSUs, were made in accordance with Nasdaq Listing Rule 5635(c)(4) under the company's 2023 Inducement Plan. The awards have a four-year vesting period, subject to continued employment.
2026-07-30 15:40:21
BlackRock, Inc. has disclosed a 5.7% beneficial ownership stake in VOR Biopharma Inc. through a Schedule 13G filing. The investment firm, along with its business units, beneficially owns 3,099,259 shares, with sole voting power over 3,057,613 shares. BlackRock indicates that this passive investment is not intended to change or influence the control of VOR Biopharma.
2026-07-30 06:09:19
This article provides the quarterly and annual income statements for Vor Biopharma Inc (VOR), detailing financial figures such as operating expenses, R&D expenses, operating profit, and net income over several fiscal years and quarters. It also includes frequently asked questions about interpreting income statements and key metrics for analyzing VOR stock. The company's net income for fiscal year 2025 was -695.98M, and its recent quarterly net income was -219.59M.
2026-07-28 02:39:43
This article provides a technical analysis of Vor Biopharma Inc (VOR), including support, resistance, indicators, and moving averages. It summarizes various technical indicators such as MACD, RSI, and STOCH, along with explanations of technical ratings and moving averages. The analysis concludes with a "Neutral" signal based on moving averages and other technical indicators.
